

February 19, 2026
J-Pharma Co., Ltd.

Notice of Approval for Listing on the Tokyo Stock Exchange Growth Market

J-Pharma Co., Ltd. (Head Office: Minato-ku, Tokyo; President & CEO: Masuhiro Yoshitake; Securities Code: 520A) hereby announces that today it has received approval from the Tokyo Stock Exchange, Inc. ("TSE") for the initial listing of its shares on the TSE Growth Market. The listing on the TSE Growth Market is scheduled for March 25, 2026. We would like to take this opportunity to respectfully announce our listing and express our sincere appreciation to all our stakeholders who have supported our company to date for their continued encouragement.

The Company leverages its proprietary research platform targeting SLC transporters as a strength to create innovative new medicines in disease areas with high unmet medical needs. Under a development strategy with a global perspective, we are steadily advancing our research and development activities, aiming to achieve sustainable corporate growth and enhance social value. As a leading company in the development of LAT1 inhibitors, we have achieved the following progress across our two key development programs:

- **LAT1 inhibitor nanvuranlat:** Initiated a global Phase 3 clinical trial for the 2nd-line treatment of biliary tract cancer.
- **LAT1 inhibitor JPH034:** Received notification from the U.S. Food and Drug Administration (FDA), dated February 12, 2026 (U.S. time), that the safety review of the Investigational New Drug (IND) application submitted for the treatment of multiple sclerosis has been completed and that the Company may proceed with the initiation of the clinical trial.

About J-Pharma Co., Ltd.

Our corporate philosophy is to "By pursuing new possibilities for SLC transporters and developing innovative new drugs that address unmet medical needs, we will contribute to supporting people around the world to maintain good health and hope." Based on this philosophy, we will work to create innovative pharmaceuticals to achieve sustainable corporate growth and increase social value. For more information, please visit: <https://www.j-pharma.com/en/>

Inquiries:

J-Pharma Co., Ltd.
Planning Department

TEL: +81-3-6432-4270

<https://www.j-pharma.com/en/contact>

Important Notice

This press release does not constitute a part of any offering of securities. This press release has been prepared for the purpose of publicly announcing the approval of the listing of the Company's shares on the Tokyo Stock Exchange Growth Market and has not been prepared for the purpose of soliciting investments, whether within or outside Japan. Any final decision regarding investment should be made at the discretion of investors after carefully reviewing the prospectus for the issuance of new shares and the secondary offering of shares (including any amendments thereto) prepared by the Company. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States. The securities referred to herein may not be offered or sold in the United States absent registration under the U.S. Securities Act of 1933, or an applicable exemption from the registration requirements thereof. No offering of securities will be made in the United States in connection with this matter.